Loading organizations...
§ Venture Capital · Shenzhen, Guangdong, China
Private equity fund management company investing in artificial intelligence, semiconductors, and biomedicine.
HongTao Capital is a private equity fund management company based in Shenzhen, Guangdong, China, strategically investing across the artificial intelligence, semiconductors, and biomedicine sectors. The firm focuses on identifying and backing high-potential technology and life science companies, providing capital to fuel their development and market expansion. While specific financial metrics like assets under management or total capital deployed are not publicly disclosed, HongTao Capital has demonstrated its investment activity through participation in various financing rounds. Its notable portfolio companies include Sirnaomics, which received investment during its US$105 million Series D financing on October 26, 2020, and MagicRNA, where the firm participated in a Seed - III round on January 16, 2024. HongTao Capital also led a seed round for Hongxin Biology on approximately August 10, 2025.
HongTao Capital has 1 tracked investment across 1 company. The latest tracked deal is $105.0M Series D in Sirnaomics in October 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 26, 2020 | Sirnaomics | $105.0M Series D | Donald DAI, SHI Shenghao, Yunchun LI | Alpha WIN Capital, Longmen Capital, Sangel Capital |